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Abstract
Brain metastases are a rare complication of prostate cancer. They are usually diagnosed in an end-stage disease when the 
tumor has already spread to the other organs and tissues. We present a case of a male with castration-resistant prostate cancer 
with bone metastases visualized in 18F-fluorocholine PET/CT scan.
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Background
Prostate cancer is the second most frequently diagnosed 
cancer and the fifth leading cause of cancer death in males world-
wide [1]. The main therapeutic approach for men with locally 
advanced or metastatic disease is currently androgen deprivation 
therapy (ADT) [2]. The strategies of ADT include surgical castra-
tion (bilateral orchidectomy), medical castration (administration of 
estrogens, LH-RH agonists or antagonists), combined androgen 
blockade (surgical castration or a LH-RH agonist combined with 
a non-steroidal antiandrogen), antiandrogen monotherapy or inter-
mittent androgen deprivation [2, 3]. In case of castration-resistant 
prostate cancer (CRPC) the available treatments are chemotherapy 
(docetaxel, cabazitaxel) or hormonal therapy with abiraterone or 
enzalutamide [4–6]. 
The most common metastatic sites of prostate adenocarcinoma 
are bone (84%), distant lymph nodes (10.6%), liver (10.2%), and 
thorax (9.1%) [7]. Brain metastases are rare and usually appear 
many years after initial diagnosis [8]. However, their incidence 
seems to be more frequent than in the past, possibly because of 
the advances in the CRPC treatment that have prolonged patients’ 
survival [9, 10].
Case report
Here we report a case of a 65-year-old male with prostate cancer 
who was diagnosed with 18F-fluorocholine avid brain metastases in 
PET/CT scan.
The disease (poorly differentiated T3a prostate adenocarci-
noma, Gleason score 7) was diagnosed in 2009 and was primarily 
treated with radical radiotherapy. PET/CT scan performed at that 
time showed bilateral lung metastases. Androgen deprivation 
therapy was initiated, followed by lung lesions resection. During 
the course of LH analogue treatment we observed the decrease 
of serum testosterone to a castrate level and a gradual increase 
of PSA levels which consequently yielded the diagnosis of CRPC. 
The second PET/CT scan performed after a three-month therapy 
showed 18F-fluorocholine avid prostate metastases in mediastinal 
lymph nodes and Th1 vertebral body. The spread of the disease 
led to the initiation of chemotherapy with docetaxel. The treat-
ment was continued despite rising PSA levels as it alleviated pa-
tient’s bone pains. Bone scintigraphy performed four months later 
(September 2012) yielded further progression of the disease in 
the skeletal system – metastases were visualized in the skull, ribs, 
thoracic and lumbar vertebrae as well as bones of the pelvis (Fig-
ure 1). The third 18F-fluorocholine PET/CT scan was performed 
in December 2012. We observed multiple lesions with increased 
18F-fluorocholine uptake in both lungs, chest lymph nodes, bones, 
subcutaneous tissue and brain (Figure 2). MRI exam performed 
subsequently confirmed the metastatic etiology of brain lesions. 
The patient initiated chemotherapy with cabazitaxel and was then 
lost to follow-up.
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Discussion
Brain metastases are a rare complication of prostate cancer. 
Their incidence at autopsy varies from 0.4% to 4.4% but is, however, 
expected to increase with improving patient survival. Brain metasta-
ses are mostly located in the leptomeninges (67%), cerebrum (25%) 
and cerebellum (8%) and usually occur in patients with end-stage 
disease who already have lesions in the skeleton, lymph nodes, 
lungs and liver [9–12]. 
Prostatic neoplastic cells seem to have a low affinity for cerebral 
tissue [13]. There are, however, several mechanisms of intracranial 
dissemination of the disease. The most common is the direct ex-
tension from a skull metastasis, which leads to the development 
of subdural lesions. The other mechanisms are hematogenic lym-
phatic spread (gives rise to both subdural and intraparenchymal 
metastases) and vascular embolization [10, 14]. 
Patients with brain metastases have a poor prognosis and 
most of them die within 4–6 months after the diagnosis [15]. 
This is partially because we are still lacking chemotherapeutic 
agents that could effectively control brain metastases — most of 
them are incapable of crossing the blood-brain barrier. Moreover, 
they are often substrates for drug efflux transporters which actively 
remove them from brain tissue. Docetaxel shows only limited activ-
ity against brain metastases. Cabazitaxel, however, reaches high 
concentrations in the cerebrum and has been proven effective 
against brain tumors. There are also some promising data concern-
ing abiraterone, CYP17 inhibitor [10]. 
18F-fluorocholine PET/CT proved to be an effective imaging mo-
dality in restaging patients with a biochemical relapse of prostate 
cancer. It is reported to have a sensitivity of 41–100%, a specificity 
of 97–100%, and an accuracy of 84–93% [16]. Currently it seems to 
be the most accurate single-step exam to identify the location of 
recurrent disease. Furthermore, it has been observed that the 
results of 18F-fluorocholine PET/CT may cause a change in the 
treatment plan for up to 48% of patients with recurrent prostate 
cancer [17]. 
Conclusion
To sum up, brain is a rare but increasing metastatic site of 
prostatic cancer. Currently there are limited data concerning the 
efficacy of the use of chemotherapeutic agents in such a clinical 
setting. 18F-fluorocholine PET/CT remains the method of choice for 
restaging biochemically relapsed prostate cancer.
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